(Q43855068)
Statements
Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi (English)
R Dietze
S F Carvalho
L C Valli
J Berman
T Brewer
W Milhous
J Sanchez
B Schuster
1 December 2001